

Mentz Rj

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3938371/publications.pdf>

Version: 2024-02-01

373
papers

13,427
citations

34076

52
h-index

33869

99
g-index

396
all docs

396
docs citations

396
times ranked

13451
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	13.9	1,455
2	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 105-113.	5.5	451
3	Palliative Care in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 331-341.	1.2	425
4	Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2281-2293.	1.2	424
5	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. <i>Circulation</i> , 2019, 140, e294-e324.	1.6	342
6	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. <i>Nature Medicine</i> , 2022, 28, 568-574.	15.2	341
7	Physical Rehabilitation for Older Patients Hospitalized for Heart Failure. <i>New England Journal of Medicine</i> , 2021, 385, 203-216.	13.9	267
8	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 136-145.	1.9	265
9	Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1081.	3.8	238
10	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 741-748.	1.6	235
11	Efficacy and Safety of Spironolactone in Acute Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 950.	3.0	199
12	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163.	1.0	195
13	Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1399-1406.	1.2	171
14	Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 194-202.	2.9	155
15	Diuretics and Ultrafiltration in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2145-2153.	1.2	142
16	Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults ≥ 60 Years With Acute Decompensated Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005254.	1.6	129
17	Pathophysiology and clinical evaluation of acute heart failure. <i>Nature Reviews Cardiology</i> , 2016, 13, 28-35.	6.1	120
18	Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1401-1411.	2.9	119

#	ARTICLE	IF	CITATIONS
19	Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?. <i>Journal of Cardiac Failure</i> , 2016, 22, 182-189.	0.7	118
20	Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1668-1682.	1.2	116
21	The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. <i>European Journal of Heart Failure</i> , 2012, 14, 605-612.	2.9	115
22	Decongestion in acute heart failure. <i>European Journal of Heart Failure</i> , 2014, 16, 471-482.	2.9	113
23	10-Year Risk Equations for Incident Heart Failure in the General Population. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2388-2397.	1.2	107
24	Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 305-309.	1.9	101
25	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013, 167, 1677-1687.	0.8	97
26	Cigarette Smoking and Incident Heart Failure. <i>Circulation</i> , 2018, 137, 2572-2582.	1.6	96
27	Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 97-107.	1.9	95
28	Outpatient Worsening Heart Failure as a Target for Therapy. <i>JAMA Cardiology</i> , 2018, 3, 252.	3.0	90
29	Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. <i>European Journal of Heart Failure</i> , 2012, 14, 395-403.	2.9	85
30	Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure. <i>American Heart Journal</i> , 2020, 229, 1-17.	1.2	85
31	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	1.9	84
32	A reappraisal of loop diuretic choice in heart failure patients. <i>American Heart Journal</i> , 2015, 169, 323-333.	1.2	83
33	Reassessing Recipient Mortality Under the New Heart Allocation System. <i>JACC: Heart Failure</i> , 2020, 8, 548-556.	1.9	83
34	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCCEL) trial. <i>American Heart Journal</i> , 2016, 174, 103-110.	1.2	82
35	Charting a Roadmap for Heart Failure Biomarker Studies. <i>JACC: Heart Failure</i> , 2014, 2, 477-488.	1.9	81
36	Good Clinical Practice Guidance and Pragmatic Clinical Trials. <i>Circulation</i> , 2016, 133, 872-880.	1.6	79

#	ARTICLE	IF	CITATIONS
37	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 507-517.	1.9	78
38	Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: Findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). <i>American Heart Journal</i> , 2013, 165, 193-199.	1.2	77
39	Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2231.	3.8	72
40	Home-Time After Discharge Among Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2643-2652.	1.2	72
41	Association of Beta-Blocker Use and Selectivity With Outcomes in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease (from OPTIMIZE-HF). <i>American Journal of Cardiology</i> , 2013, 111, 582-587.	0.7	71
42	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. <i>European Journal of Heart Failure</i> , 2014, 16, 614-624.	2.9	71
43	Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale. <i>American Heart Journal</i> , 2017, 185, 130-139.	1.2	71
44	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3029-3039.	1.2	69
45	Regional adiposity and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1540-1550.	2.9	69
46	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. <i>Circulation</i> , 2022, 146, 279-288.	1.6	65
47	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020, 43, 446-452.	4.3	63
48	The Impact of Chronic Obstructive Pulmonary Disease in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction: An Analysis of the EVEREST Trial. <i>Journal of Cardiac Failure</i> , 2012, 18, 515-523.	0.7	62
49	Frailty Among Older Decompensated Heart Failure Patients. <i>JACC: Heart Failure</i> , 2019, 7, 1079-1088.	1.9	61
50	Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure. <i>Circulation</i> , 2020, 142, 230-243.	1.6	59
51	Relationship Between Clinical Trial Site Enrollment With Participant Characteristics, Protocol Completion, and Outcomes. <i>Journal of the American College of Cardiology</i> , 2013, 61, 571-579.	1.2	58
52	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes. <i>Circulation</i> , 2019, 140, 1613-1622.	1.6	58
53	Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. <i>Circulation</i> , 2021, 143, 2370-2383.	1.6	56
54	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Trial. <i>Circulation</i> , 2014, 129, 1079-1088.	1.2	54

#	ARTICLE	IF	CITATIONS
55	Increasing the United States heart transplant donor pool with donation after circulatory death. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, e307-e309.	0.4	53
56	Noncardiac Comorbidities and Acute Heart Failure Patients. <i>Heart Failure Clinics</i> , 2013, 9, 359-367.	1.0	52
57	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2015, 8, 1044-1051.	1.6	52
58	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , 2017, 187, 1-9.	1.2	49
59	Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 202-210.	0.3	49
60	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline. <i>Circulation</i> , 2019, 140, 2076-2088.	1.6	49
61	In-Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	48
62	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. <i>Heart Failure Reviews</i> , 2014, 19, 135-152.	1.7	48
63	Heart Failure Clinical Trials in East and Southeast Asia. <i>JACC: Heart Failure</i> , 2016, 4, 419-427.	1.9	48
64	Population-Attributable Risk for Cardiovascular Disease Associated With Hypertension in Black Adults. <i>JAMA Cardiology</i> , 2019, 4, 1194.	3.0	48
65	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 138.	2.7	48
66	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2004-2012.	1.2	48
67	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016, 117, 404-411.	0.7	47
68	Can Vaccinations Improve Heart Failure Outcomes?. <i>JACC: Heart Failure</i> , 2017, 5, 194-203.	1.9	47
69	Global Perspectives in Hospitalized Heart Failure: Regional and Ethnic Variation in Patient Characteristics, Management, and Outcomes. <i>Current Heart Failure Reports</i> , 2014, 11, 416-427.	1.3	46
70	The Palliative Care in Heart Failure Trial: Rationale and design. <i>American Heart Journal</i> , 2014, 168, 645-651.e1.	1.2	45
71	Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1683-1691.	1.2	45
72	Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. <i>American Heart Journal</i> , 2020, 219, 47-57.	1.2	45

#	ARTICLE	IF	CITATIONS
73	Implications of geographical variation on clinical outcomes of cardiovascular trials. American Heart Journal, 2012, 164, 303-312.	1.2	44
74	Characteristics and Trends Among Patients With Cardiovascular Disease Referred to Palliative Care. JAMA Network Open, 2019, 2, e192375.	2.8	43
75	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. European Journal of Heart Failure, 2018, 20, 304-314.	2.9	42
76	Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial. American Heart Journal, 2018, 204, 163-173.	1.2	42
77	Clinical profiles in acute heart failure: an urgent need for a new approach. ESC Heart Failure, 2019, 6, 464-474.	1.4	42
78	Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION. European Journal of Heart Failure, 2019, 21, 63-70.	2.9	42
79	Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes, 2018, 67, .	0.3	42
80	Achieving a Maximally Tolerated β -Blocker Dose in Heart Failure Patients. Journal of the American College of Cardiology, 2017, 69, 2542-2550.	1.2	41
81	Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2021, 6, 918-932.	1.9	41
82	Response to Exercise Training and Outcomes in Patients With Heart Failure and Diabetes Mellitus: Insights From the HF-ACTION Trial. Journal of Cardiac Failure, 2016, 22, 485-491.	0.7	40
83	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. European Journal of Heart Failure, 2013, 15, 456-464.	2.9	39
84	Inclusion and diversity in clinical trials: Actionable steps to drive lasting change. Contemporary Clinical Trials, 2022, 116, 106740.	0.8	39
85	Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). American Heart Journal, 2015, 170, 298-305.	1.2	38
86	Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans. JAMA Cardiology, 2019, 4, 51.	3.0	38
87	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care, 2020, 43, 643-652.	4.3	38
88	Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure. JACC: Heart Failure, 2021, 9, 471-481.	1.9	38
89	Comorbidities in Heart Failure: Are There Gender Differences?. Current Heart Failure Reports, 2016, 13, 1-12.	1.3	37
90	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. European Journal of Heart Failure, 2016, 18, 306-313.	2.9	36

#	ARTICLE	IF	CITATIONS
91	Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 362-369.	0.3	36
92	Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. <i>JACC: Heart Failure</i> , 2019, 7, 371-382.	1.9	36
93	Relation of Dyspnea Severity on Admission for Acute Heart Failure With Outcomes and Costs. <i>American Journal of Cardiology</i> , 2015, 115, 75-81.	0.7	35
94	Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. <i>Journal of Cardiac Failure</i> , 2016, 22, 884-890.	0.7	35
95	Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	35
96	The role of angiotensin receptorâ€œneprilysin inhibitors in cardiovascular diseaseâ€œexisting evidence, knowledge gaps, and future directions. <i>European Journal of Heart Failure</i> , 2018, 20, 963-972.	2.9	35
97	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408.	1.6	34
98	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. <i>American Heart Journal</i> , 2014, 168, 142-149.	1.2	34
99	Bronchodilators in Heart Failure Patients With COPD: Is It Time for a Clinical Trial?. <i>Journal of Cardiac Failure</i> , 2012, 18, 413-422.	0.7	33
100	Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 251-258.	1.2	33
101	Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes. <i>American Heart Journal</i> , 2017, 183, 54-61.	1.2	33
102	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1390-1398.	2.9	33
103	Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. <i>Circulation</i> , 2022, 146, 808-818.	1.6	33
104	Comparison of Clinical Characteristics and Long-Term Outcomes of Patients With Ischemic Cardiomyopathy With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular) Tj ETQq0 0 0 ngBT /Overlock 10 Tf 5	0.8	32
105	Sleep Breathing Disorders in Heart Failure. <i>Heart Failure Clinics</i> , 2020, 16, 45-51.	1.0	32
106	Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 747-757.	1.9	32
107	Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial. <i>Circulation</i> , 2022, 146, 80-90.	1.6	32
108	Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. <i>American Heart Journal</i> , 2017, 191, 75-81.	1.2	31

#	ARTICLE	IF	CITATIONS
109	Learning from recent trials and shaping the future of acute heart failure trials. <i>American Heart Journal</i> , 2013, 166, 629-635.	1.2	30
110	Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME). <i>Journal of the American College of Cardiology</i> , 2016, 68, 1815-1817.	1.2	30
111	Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals. <i>JAMA Cardiology</i> , 2017, 2, 644.	3.0	30
112	Vaccination Trends in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 844-855.	1.9	30
113	Representativeness of a Heart Failure Trial by Race and Sex. <i>JACC: Heart Failure</i> , 2019, 7, 980-992.	1.9	30
114	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. <i>Circulation: Heart Failure</i> , 2021, 14, e008100.	1.6	30
115	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 826-836.	0.7	30
116	Race, exercise training, and outcomes in chronic heart failure: Findings from Heart Failure - A Controlled Trial Investigating Outcomes in Exercise Training (HF-ACTION). <i>American Heart Journal</i> , 2013, 166, 488-495.e1.	1.2	29
117	Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?. <i>European Journal of Heart Failure</i> , 2017, 19, 974-986.	2.9	29
118	Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 525-532.	2.9	29
119	Sex Differences in Quality of Life and Clinical Outcomes in Patients With Advanced Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006134.	1.6	29
120	Torsemide Versus Furosemide in Heart Failure Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 65, 438-443.	0.8	28
121	Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact. <i>Journal of Cardiac Failure</i> , 2015, 21, 741-750.	0.7	28
122	Atherosclerosis: Recent trials, new targets and future directions. <i>International Journal of Cardiology</i> , 2015, 192, 72-81.	0.8	28
123	Discharge heart rate and β -blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. <i>American Heart Journal</i> , 2016, 173, 172-178.	1.2	28
124	Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 293-300.	1.9	28
125	Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial. <i>American Heart Journal</i> , 2017, 186, 130-138.	1.2	27
126	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial—insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1022-1031.	2.9	27

#	ARTICLE	IF	CITATIONS
127	Tolvaptan in Patients Hospitalized With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 997-1005.	1.6	26
128	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.7	26
129	Effect of once-a-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A <i>post hoc</i> analysis of the <i>EXSCEL</i> trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2493-2498.	2.2	26
130	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008018.	1.4	25
131	Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: Findings from the EVEREST Trial. <i>American Heart Journal</i> , 2012, 164, 884-892.e2.	1.2	24
132	Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 697-706.	2.9	24
133	Strategies for supporting intervention fidelity in the rehabilitation therapy in older acute heart failure patients (REHAB-HF) trial. <i>Contemporary Clinical Trials</i> , 2018, 64, 118-127.	0.8	24
134	Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks. <i>Circulation: Heart Failure</i> , 2018, 11, e005629.	1.6	24
135	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. <i>Circulation</i> , 2018, 138, 1039-1053.	1.6	24
136	Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals. <i>JAMA Cardiology</i> , 2020, 5, 871.	3.0	24
137	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007871.	1.6	24
138	Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. <i>Future Cardiology</i> , 2015, 11, 585-595.	0.5	23
139	Usefulness of Palliative Care to Complement the Management of Patients on Left Ventricular Assist Devices. <i>American Journal of Cardiology</i> , 2016, 118, 733-738.	0.7	23
140	Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. <i>American Journal of Cardiology</i> , 2016, 117, 946-951.	0.7	23
141	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2016, 117, 1144-1150.	0.7	23
142	Resting Heart Rate and Long-term Outcomes Among the African American Population. <i>JAMA Cardiology</i> , 2017, 2, 172.	3.0	23
143	Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , 2018, 20, 1281-1289.	2.9	23
144	Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. <i>Diabetes Care</i> , 2019, 42, 318-326.	4.3	23

#	ARTICLE	IF	CITATIONS
145	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 336-345.	1.9	23
146	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 1063-1077.	0.7	23
147	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. <i>European Journal of Heart Failure</i> , 2022, 24, 996-1005.	2.9	23
148	Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 241-249.	2.9	22
149	Influence of Baseline Physical Activity Level on Exercise Training Response and Clinical Outcomes in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 1011-1019.	1.9	22
150	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. <i>Clinical Cardiology</i> , 2018, 41, 945-952.	0.7	22
151	Pragmatic Design of Randomized Clinical Trials for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 325-335.	1.9	22
152	The need for increased pragmatism in cardiovascular clinical trials. <i>Nature Reviews Cardiology</i> , 2022, 19, 737-750.	6.1	22
153	Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 61-68.	2.9	21
154	Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 365-373.	1.0	21
155	Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 1056-1065.	1.9	21
156	Cognition, Physical Function, and Quality of Life in Older Patients With Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 286-294.	0.7	21
157	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2022, 79, 504-510.	1.2	21
158	Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018. <i>JACC: Heart Failure</i> , 2022, 10, 350-362.	1.9	21
159	Ventricular Conduction and Long-Term Heart Failure Outcomes and Mortality in African Americans. <i>Circulation: Heart Failure</i> , 2015, 8, 243-251.	1.6	20
160	Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015, 169, 305-314.	1.2	20
161	Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	20
162	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 1747-1755.	1.4	20

#	ARTICLE	IF	CITATIONS
163	The Obesity and Heart Failure Epidemics Among African Americans: Insights From the Jackson Heart Study. <i>Journal of Cardiac Failure</i> , 2016, 22, 589-597.	0.7	19
164	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCeL Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009304.	1.6	19
165	Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1097-1105.	0.8	19
166	Cigarette Smoking and Incident Stroke in Blacks of the Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2020, 9, e014990.	1.6	19
167	Cigarette Smoking, Incident Coronary Heart Disease, and Coronary Artery Calcification in Black Adults: The Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2021, 10, e017320.	1.6	19
168	Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 876-886.	1.9	19
169	Influence of donor brain death duration on outcomes following heart transplantation: A United Network for Organ Sharing Registry analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 1345-1353.e2.	0.4	18
170	Sample size requirements for detecting treatment effect heterogeneity in cluster randomized trials. <i>Statistics in Medicine</i> , 2020, 39, 4218-4237.	0.8	18
171	Donation After Circulatory Death in Heart Transplantation: History, Outcomes, Clinical Challenges, and Opportunities to Expand the Donor Pool. <i>Journal of Cardiac Failure</i> , 2022, 28, 1456-1463.	0.7	18
172	Trends in Place of Death for Individuals With Cardiovascular Disease in the United States. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1943-1946.	1.2	17
173	Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events. <i>European Journal of Heart Failure</i> , 2014, 16, 854-860.	2.9	16
174	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	0.7	16
175	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	15
176	Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Tj ETQq0 0 0 rgBT /Overlock 10 TF	0.7	15
177	Intentional and unintentional medication non-adherence in African Americans: Insights from the Jackson Heart Study. <i>American Heart Journal</i> , 2018, 200, 51-59.	1.2	15
178	Neck circumference and cardiovascular outcomes: Insights from the Jackson Heart Study. <i>American Heart Journal</i> , 2019, 212, 72-79.	1.2	15
179	Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 223-225.	0.6	15
180	Epidemiology of Cardiorenal Syndrome. <i>Heart Failure Clinics</i> , 2010, 6, 333-346.	1.0	14

#	ARTICLE	IF	CITATIONS
181	Prognostic Significance of Depression in Blacks With Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 497-503.	1.6	14
182	Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. <i>European Journal of Heart Failure</i> , 2016, 18, 684-692.	2.9	14
183	Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). <i>American Heart Journal</i> , 2016, 178, 198-205.	1.2	14
184	Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial. <i>American Heart Journal</i> , 2018, 204, 202-204.	1.2	14
185	Depressive symptoms, physical activity, and clinical events: The ADAPT prospective pilot study. <i>Clinical Transplantation</i> , 2019, 33, e13710.	0.8	14
186	Patients' Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008051.	1.4	14
187	Regional Adiposity and Risk of Heart Failure and Mortality: The Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2021, 10, e020920.	1.6	14
188	Natriuretic Peptide-Guided Therapy for Heart Failure. <i>Circulation Journal</i> , 2011, 75, 2031-2037.	0.7	13
189	Sleep-Disordered Breathing in Patients with Heart Failure. <i>Heart Failure Clinics</i> , 2014, 10, 243-250.	1.0	13
190	Longitudinal Strain in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2015, 132, 368-370.	1.6	13
191	Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. <i>Clinical Cardiology</i> , 2017, 40, 38-45.	0.7	13
192	Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 2576-2578.	1.6	13
193	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783.	0.9	13
194	Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION. <i>American Heart Journal</i> , 2018, 205, 133-141.	1.2	13
195	Drugs of Abuse and Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 1260-1275.	0.7	13
196	Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. <i>Journal of Cardiac Failure</i> , 2021, 27, 1374-1381.	0.7	13
197	Interaction of Body Mass Index on the Association Between N-Terminal Pro-B-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study) Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004783.	1.0	12
198	Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX. <i>American Journal of Medicine</i> , 2020, 133, e716-e721.	0.6	12

#	ARTICLE	IF	CITATIONS
199	Predischarge initiation of Ivabradine in the Management of Heart Failure: Results of the PRIME-HF Trial. <i>American Heart Journal</i> , 2020, 223, 98-105.	1.2	12
200	Spirolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1451-1461.	2.9	12
201	Participation in a Heart Failure Clinical Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008242.	1.6	12
202	A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response. <i>American Heart Journal</i> , 2020, 225, 3-9.	1.2	12
203	Spirituality in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 217-226.	1.9	12
204	End-of-life Heart Failure Care in the United States. <i>Heart Failure Clinics</i> , 2015, 11, 615-623.	1.0	11
205	Acute heart failure in the young: Clinical characteristics and biomarker profiles. <i>International Journal of Cardiology</i> , 2016, 221, 1067-1072.	0.8	11
206	Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). <i>American Journal of Cardiology</i> , 2016, 118, 1211-1216.	0.7	11
207	Cardiorenal Interactions. <i>Heart Failure Clinics</i> , 2016, 12, 335-347.	1.0	11
208	Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Left Ventricular Assist Devices. <i>Journal of Palliative Medicine</i> , 2019, 22, 437-441.	0.6	11
209	Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. <i>Journal of the American Heart Association</i> , 2020, 9, e015752.	1.6	11
210	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 799-809.	0.6	10
211	Site Principal Investigators in Multicenter Clinical Trials. <i>Circulation</i> , 2017, 135, 1185-1187.	1.6	10
212	Trends and outcomes of cardiac transplantation from donors dying of drug intoxication. <i>American Heart Journal</i> , 2018, 199, 92-96.	1.2	10
213	Hyperkalemia in Heart Failure: Probably Not. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	10
214	The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. <i>Clinical Cardiology</i> , 2018, 41, 1259-1267.	0.7	10
215	Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults. <i>JACC: Heart Failure</i> , 2021, 9, 484-493.	1.9	10
216	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021459.	1.6	10

#	ARTICLE	IF	CITATIONS
217	Epidemiology of Cardiorenal Syndrome. <i>Cardiology Clinics</i> , 2011, 29, 301-314.	0.9	9
218	Statins and Exercise Training Response in Heart Failure Patients. <i>JACC: Heart Failure</i> , 2016, 4, 617-624.	1.9	9
219	Air Pollution in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 65-67.	1.9	9
220	Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. <i>American Heart Journal</i> , 2018, 199, 97-104.	1.2	9
221	Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. <i>Clinical Cardiology</i> , 2019, 42, 256-263.	0.7	9
222	Relation of Early Repolarization (J Point Elevation) to Mortality in Blacks (from the Jackson Heart Study). <i>Journal of the American Heart Association</i> , 2019, 10, e01505.	0.7	9
223	African Americans With Advanced Heart Failure Are More Likely to Die in a Health Care Facility Than at Home or in Hospice: An Analysis From the PAL-HF Trial. <i>Journal of Cardiac Failure</i> , 2019, 25, 693-694.	0.7	9
224	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCCEL Outcomes. <i>Circulation</i> , 2020, 141, 1360-1370.	1.6	9
225	Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults. <i>JACC: Heart Failure</i> , 2022, 10, 129-138.	1.9	9
226	Depressive Symptoms and Incident Heart Failure in the Jackson Heart Study: Differential Risk Among Black Men and Women. <i>Journal of the American Heart Association</i> , 2022, 11, e022514.	1.6	9
227	Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014, 114, 743-750.	0.7	8
228	Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. <i>American Heart Journal</i> , 2015, 170, 1124-1132.	1.2	8
229	Assessment of Administrative Data to Identify Acute Myocardial Infarction in Electronic Health Records. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2441-2442.	1.2	8
230	Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2018, 200, 134-140.	1.2	8
231	Hospice Care for Heart Failure: Challenges Faced by Hospice Staff in a Predominantly Rural Setting. <i>Journal of Palliative Medicine</i> , 2019, 22, 7-8.	0.6	8
232	PROVIDE-HF primary results: Patient-Reported Outcomes in Investigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. <i>American Heart Journal</i> , 2020, 230, 35-43.	1.2	8
233	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006758.	1.6	8
234	Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2021, 145, 165-168.	0.7	8

#	ARTICLE	IF	CITATIONS
235	The Cost-Effectiveness of Palliative Care: Insights from the PAL-HF Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 662-669.	0.7	8
236	Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 568-577.	1.9	8
237	Clinical Outcome Predictions for the VeriCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 949-956.	0.7	8
238	Physical Rehabilitation in Older Patients Hospitalized with Acute Heart Failure and Diabetes: Insights from REHAB-HF. <i>American Journal of Medicine</i> , 2022, 135, 82-90.	0.6	8
239	Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. <i>American Journal of Cardiology</i> , 2020, 127, 64-72.	0.7	8
240	A Call for Collaboration. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2348-2351.	1.2	7
241	Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	7
242	Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. <i>Journal of Cardiac Failure</i> , 2016, 22, 853-858.	0.7	7
243	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 435-450.	1.2	7
244	Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. <i>American Heart Journal</i> , 2020, 226, 13-23.	1.2	7
245	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 808-811.	0.7	7
246	Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?. <i>American Heart Journal</i> , 2020, 226, 69-74.	1.2	7
247	Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008797.	1.6	7
248	Gender Does Not Affect Postdischarge Outcomes in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 21</i>	0.7	6
249	Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , 2017, 14, 30-39.	1.3	6
250	Top Ten Tips for Palliative Care Clinicians Caring for Heart Failure Patients. <i>Journal of Palliative Medicine</i> , 2018, 21, 1646-1650.	0.6	6
251	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 21</i>	0.7	6
252	Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center. <i>American Heart Journal</i> , 2020, 230, 25-34.	1.2	6

#	ARTICLE	IF	CITATIONS
253	Acute cardiovascular hospitalizations and illness severity before and during the <scp>COVID</scp>â€19 pandemic. <i>Clinical Cardiology</i> , 2021, 44, 656-664.	0.7	6
254	Thoughtful selection and use of scientific terms in clinical research: the case of â€pragmaticâ€™ trials. <i>Journal of Investigative Medicine</i> , 2021, 69, 1056-1058.	0.7	6
255	Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event. <i>Journal of Medical Economics</i> , 2021, 24, 698-705.	1.0	6
256	Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. <i>Journal of the American Heart Association</i> , 2021, 10, e021276.	1.6	6
257	Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCCEL trial. <i>Atherosclerosis</i> , 2021, 338, 1-6.	0.4	6
258	An evaluation of torsemide in patients with heart failure and renal disease. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 5-11.	0.6	6
259	Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 1349-1354.	0.7	6
260	Cardiorenal Syndrome Clinical Trial End Points. <i>Heart Failure Clinics</i> , 2011, 7, 519-528.	1.0	5
261	Dysphagia in the Setting of Left Ventricular Assist Device Hemolysis. <i>ASAIO Journal</i> , 2013, 59, 322-323.	0.9	5
262	Is There a Rationale for Antiplatelet Therapy in Acute Heart Failure?. <i>Circulation: Heart Failure</i> , 2013, 6, 869-876.	1.6	5
263	Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America. <i>Heart Failure Clinics</i> , 2015, 11, 581-589.	1.0	5
264	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. <i>American Journal of Cardiology</i> , 2015, 116, 1304-1310.	0.7	5
265	Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	5
266	Paving a Better Path for Patients Dying of Heart Disease. <i>Circulation</i> , 2018, 137, 1216-1217.	1.6	5
267	Renal Function and Exercise Training in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 122, 999-1007.	0.7	5
268	Renal Outcomes in Patients Bridged to Heart Transplant With a Left Ventricular Assist Device. <i>Annals of Thoracic Surgery</i> , 2020, 110, 567-574.	0.7	5
269	Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example. <i>Contemporary Clinical Trials</i> , 2020, 88, 105775.	0.8	5
270	In-hospital outcomes after bariatric surgery in patients with heart failure. <i>American Heart Journal</i> , 2020, 230, 59-62.	1.2	5

#	ARTICLE	IF	CITATIONS
271	A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 540-548.	1.1	5
272	Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. <i>ESC Heart Failure</i> , 2021, 8, 662-669.	1.4	5
273	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , 2021, 38, e14552.	1.2	5
274	Relationship of physical function with quality of life in older patients with acute heart failure. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1836-1845.	1.3	5
275	Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial. <i>JAMA Cardiology</i> , 2022, 7, 140.	3.0	5
276	Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 916-923.	0.7	5
277	Intervention Adherence in REHAB-HF: Predictors and Relationship With Physical Function, Quality of Life, and Clinical Events. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	5
278	Funding opportunities for clinical investigators in the early stages of career development in cardiovascular research. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 527-532.	1.0	4
279	COPD in Heart Failure. <i>Chest</i> , 2015, 147, 586-588.	0.4	4
280	Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients. <i>Journal of Cardiac Failure</i> , 2015, 21, 608-609.	0.7	4
281	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 298-307.	1.9	4
282	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019, 218, 57-65.	1.2	4
283	Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , 2020, 43, 374-381.	4.3	4
284	Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 754-758.	2.9	4
285	Hypertensive diseases in pregnancy, cardiac structure and function later in life: Insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. <i>Pregnancy Hypertension</i> , 2020, 21, 184-190.	0.6	4
286	Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 111-116.	2.3	4
287	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 297-308.	0.7	4
288	Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 322-325.	1.6	4

#	ARTICLE	IF	CITATIONS
289	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1309-1318.	1.3	4
290	Hospitalized Heart Failure in the United States. <i>Heart Failure Clinics</i> , 2015, 11, 591-601.	1.0	3
291	Can 2 Pills a Day Keep Readmission Away?. <i>Journal of the American College of Cardiology</i> , 2016, 68, 249-251.	1.2	3
292	Subcutaneous Furosemide in the Treatment of Patients with Decompensated Heart Failure: Data from the Sub-Q Pilot Studies. <i>Journal of Cardiac Failure</i> , 2019, 25, S75.	0.7	3
293	Clinical Effectiveness of Sacubitril/valsartan among Patients Hospitalized for Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2019, 25, 937.	0.7	3
294	Biomarkers in Advanced Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006840.	1.6	3
295	Relation of Low Normal Left Ventricular Ejection Fraction to Heart Failure Hospitalization in Blacks (From the Jackson Heart Study). <i>American Journal of Cardiology</i> , 2020, 136, 100-106.	0.7	3
296	The Future of the Journal of Cardiac Failure: A Reinvigorated Focus on People, Partnerships and Presentation. <i>Journal of Cardiac Failure</i> , 2021, 27, 1.	0.7	3
297	Egg Consumption and Risk of Cardiovascular Disease: a Critical Review. <i>Current Emergency and Hospital Medicine Reports</i> , 2021, 9, 25-37.	0.6	3
298	Diversity, Equity and Inclusion at the Journal of Cardiac Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 263-264.	0.7	3
299	Estimated Glomerular Filtration Rate Variability in Patients With Heart Failure and Chronic Kidney Disease. <i>Journal of Cardiac Failure</i> , 2021, 27, 1175-1184.	0.7	3
300	Sleep quality, depressive symptoms, and transplant outcomes: Follow-up analyses from the ADAPT prospective pilot study. <i>General Hospital Psychiatry</i> , 2021, 72, 53-58.	1.2	3
301	Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. <i>American Heart Journal</i> , 2021, 239, 110-119.	1.2	3
302	Dysglycemia and incident heart failure among blacks: The jackson heart study. <i>American Heart Journal</i> , 2022, 245, 1-9.	1.2	3
303	Race Differences in Quality of Life following a Palliative Care Intervention in Patients with Advanced Heart Failure: Insights from the Palliative Care in Heart Failure Trial. <i>Journal of Palliative Medicine</i> , 2022, 25, 296-300.	0.6	3
304	Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. <i>Contemporary Clinical Trials</i> , 2022, 113, 106646.	0.8	3
305	Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction. <i>American Heart Journal</i> , 2022, 245, 110-116.	1.2	3
306	Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study. <i>Journal of Cardiac Failure</i> , 2022, 28, 1267-1277.	0.7	3

#	ARTICLE	IF	CITATIONS
307	Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	3
308	Elevated Heart Rate in Patients with Heart Failure with Reduced Ejection Fraction: Associations with One-Year Survival and Costs. <i>Journal of Cardiac Failure</i> , 2015, 21, S121-S122.	0.7	2
309	Cardiac Contractility Modulation: The Next Cardiac Resynchronization Therapy or Another Renal Sympathetic Denervation?. <i>Journal of Cardiac Failure</i> , 2015, 21, 24-26.	0.7	2
310	Exercise Training in Patients with Chronic Heart Failure and Atrial Fibrillation: Results from the HF-ACTION Trial. <i>Journal of Cardiac Failure</i> , 2016, 22, S71.	0.7	2
311	TIMING AND CLINICAL PREDICTORS OF EARLY VERSUS LATE READMISSION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: INSIGHTS FROM ASCEND-HF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 766.	1.2	2
312	Early versus late readmission during the vulnerable phase following hospitalization for heart failure: reply. <i>European Journal of Heart Failure</i> , 2018, 20, 1166-1166.	2.9	2
313	Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study. <i>Journal of Clinical Apheresis</i> , 2018, 33, 469-479.	0.7	2
314	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESSâ€œHF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1472-1476.	2.9	2
315	Potassium Abnormalities Across the Spectrum of Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 77-79.	1.9	2
316	Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 85-101.	0.6	2
317	Differences between patients with cardiovascular disease and cancer referred for palliative care. <i>American Heart Journal</i> , 2021, 233, 5-9.	1.2	2
318	Older Patients With Acute Decompensated Heart Failure Who Live Alone: An Analysis From the REHAB-HF Trial. <i>Journal of Cardiac Failure</i> , 2021, , .	0.7	2
319	Survival in Patients with Non-Ischemic Cardiomyopathy with Preserved versus Reduced Ejection Fraction. <i>CJC Open</i> , 2021, 3, 1333-1340.	0.7	2
320	Hypertensive Diseases in Pregnancy and Kidney Function Later in Life. <i>Mayo Clinic Proceedings</i> , 2022, 97, 78-87.	1.4	2
321	Physical Functioning in Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2021, 27, 1002-1016.	0.7	2
322	Polypharmacy in Palliative Care for Advanced Heart Failure: The PAL-HF Experience. <i>Journal of Cardiac Failure</i> , 2022, 28, 334-338.	0.7	2
323	OptiVol for Volume Assessment in Patients With Continuous Flow Left Ventricular Assist Device. <i>ASAIO Journal</i> , 2021, 67, 192-195.	0.9	2
324	In-Hospital Outcomes in Pregnancy After Heart Transplantation. <i>American Journal of Cardiology</i> , 2022, 172, 68-72.	0.7	2

#	ARTICLE	IF	CITATIONS
325	JCF Year-In-Review 2021 and the Path Forward. Journal of Cardiac Failure, 2021, 27, 1307-1309.	0.7	2
326	Sleep Breathing Disorders in Heart Failure. Cardiology Clinics, 2022, 40, 183-189.	0.9	2
327	Â blockers for heart failure: which works best?. BMJ, The, 2013, 346, f480-f480.	3.0	1
328	Is there a role for albumin and C-reactive protein levels for prognostication in acute heart failure?. Journal of Cardiovascular Medicine, 2015, 16, 401-403.	0.6	1
329	A Gordian knot: disentangling comorbidities in heart failure. European Journal of Heart Failure, 2016, 18, 759-761.	2.9	1
330	Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial. Journal of Cardiac Failure, 2016, 22, 545-547.	0.7	1
331	Return on Investment in ImplantableÂDevices. JACC: Heart Failure, 2017, 5, 213-215.	1.9	1
332	EFFECTS OF AGE AND COMORBIDITIES ON OUTCOMES IN PATIENTS WITH HEART FAILURE FROM HF-ACTION. Journal of the American College of Cardiology, 2017, 69, 908.	1.2	1
333	Building the case for aerobic exercise in ambulatory patients with heart failure and a reduced ejection fraction. American Heart Journal, 2017, 192, e3.	1.2	1
334	Traveling the Interstices of Data Sharing. JACC: Heart Failure, 2018, 6, 533-535.	1.9	1
335	Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2018, 72, 41-44.	1.2	1
336	Patterns of Change in Quality of Life with a Palliative Care Intervention for Patients with Advanced Heart Failure: Insights from PAL-HF. Journal of Cardiac Failure, 2019, 25, S154-S155.	0.7	1
337	PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE EXSCEL TRIAL. Journal of the American College of Cardiology, 2019, 73, 2040.	1.2	1
338	Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does â€œXâ€ Really Mark the Spot?. Current Heart Failure Reports, 2019, 16, 250-256.	1.3	1
339	Patients Accept Mortality Risk for Improvements in Physical Functioning in Secondary Mitral Regurgitation. Journal of Cardiac Failure, 2019, 25, S149.	0.7	1
340	Comparison of Dyspnea Measurement Instruments in Acute Heart Failure: The DYSPNEA-AHF Pilot Study. Journal of Cardiac Failure, 2021, 27, 607-609.	0.7	1
341	Patterns of Change in Individual Domains of the Kansas City Cardiomyopathy Questionnaire With a Palliative Care Intervention for Patients With Advanced Heart Failure: Insights from PAL-HF. Journal of Cardiac Failure, 2021, 27, 1476-1478.	0.7	1
342	Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. American Heart Journal, 2021, 233, 1-4.	1.2	1

#	ARTICLE	IF	CITATIONS
343	Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications. Current Heart Failure Reports, 2021, 18, 132-143.	1.3	1
344	The Universal Definition of Heart Failure: Perspectives from Diverse Stakeholders. Journal of Cardiac Failure, 2021, 27, 386.	0.7	1
345	Worsening Heart Failure Events in HFpEF. JACC: Heart Failure, 2021, 9, 383-385.	1.9	1
346	Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study). American Journal of Cardiology, 2021, 158, 59-65.	0.7	1
347	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). American Journal of Cardiology, 2021, 154, 123-126.	0.7	1
348	Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. Circulation: Heart Failure, 2021, , CIRCHEARTFAILURE121008403.	1.6	1
349	Following Our Hearts: Prioritizing Self-care and Wellness. Journal of Cardiac Failure, 2021, 27, 1163-1164.	0.7	1
350	Heart Month – A Historical Look and Simple “Walk” of Acknowledgement in the Present. Journal of Cardiac Failure, 2022, 28, 169-170.	0.7	1
351	Association between VE-VCO2 Slope and Resting Hemodynamic Measurements in Ambulatory Heart Failure (HF) Patients: An Analysis from the Duke Advanced HF Database. Journal of Cardiac Failure, 2011, 17, S8-S9.	0.7	0
352	Clinical Characteristics and Outcomes of Patients with Ischemic Cardiomyopathy (ICM) and Angina: Findings from the Duke Cardiovascular Database. Journal of Cardiac Failure, 2011, 17, S81-S82.	0.7	0
353	Clinical Characteristics and Outcomes for Hospitalized Heart Failure (HF) Patients with Chronic Obstructive Pulmonary Disease (COPD): Findings from OPTIMIZE-HF. Journal of Cardiac Failure, 2011, 17, S86-S87.	0.7	0
354	International Differences in Acute Heart Failure (AHF) Patients: Insight from the PROTECT Trial. Journal of Cardiac Failure, 2011, 17, S59-S60.	0.7	0
355	Comparable Clinical Benefits with Beta-Blockers in Heart Failure Patients from North America and Europe: Evidence from a Meta-Analysis of Randomized Clinical Trials. Journal of Cardiac Failure, 2013, 19, S28.	0.7	0
356	Response to “Global cardiovascular clinical trials and geographic altitude”. American Heart Journal, 2013, 165, e15.	1.2	0
357	SERUM MAGNESIUM LEVELS AND POSTDISCHARGE OUTCOMES IN PATIENTS HOSPITALIZED FOR HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL. Journal of the American College of Cardiology, 2013, 61, E631.	1.2	0
358	Torsemide vs. Furosemide in Heart Failure Patients: Insights from Duke University Hospital. Journal of Cardiac Failure, 2014, 20, S95.	0.7	0
359	The Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure Study: A Randomized, Double blind, Placebo-Controlled Trial in Acute Heart Failure. Journal of Cardiac Failure, 2016, 22, 939.	0.7	0
360	Regional Differences during Acute Heart Failure Hospitalizations of Patients with Heart Failure with Preserved Ejection Fraction: Insights From ASCEND-HF. Journal of Cardiac Failure, 2016, 22, S27.	0.7	0

#	ARTICLE	IF	CITATIONS
361	HEMOCONCENTRATION DURING MANAGEMENT OF PATIENTS WITH ACUTE HEART FAILURE AND CARDIORENAL SYNDROME: INSIGHTS FROM CARRESS-HF. Journal of the American College of Cardiology, 2017, 69, 767.	1.2	0
362	Loop Diuretic Change in Patients with Chronic Heart Failure: Insights From HF-ACTION. Journal of Cardiac Failure, 2017, 23, S65-S66.	0.7	0
363	The Burden of Non-Cardiac Comorbidities in Acute Heart Failure: Insights From ASCEND-HF. Journal of Cardiac Failure, 2017, 23, S109.	0.7	0
364	Causes of Death Among Patients with and without Diabetes and Chronic Heart Failure: Insights from the HF-ACTION and ASIAN-HF Registry. Journal of Cardiac Failure, 2018, 24, S69.	0.7	0
365	Increased eGFR Variability is Observed in Patients with HFrEF Compared to no HF or HFpEF in the Setting of Chronic Kidney Disease. Journal of Cardiac Failure, 2019, 25, S92.	0.7	0
366	A Case for Re-Gifting. JACC: Case Reports, 2021, 3, 1010-1012.	0.3	0
367	Early Identification of Patients at Risk for Incident Heart Failure With Preserved Ejection Fraction: Novel Approach to Echocardiographic Trends. Journal of Cardiac Failure, 2021, 27, 942-948.	0.7	0
368	Abstract 17304: Sudden Cardiac Death After Acute Heart Failure Hospitalization: Insights From ASCEND-HF. Circulation, 2015, 132, .	1.6	0
369	Volume Assessment and Management: Medical and Device Therapies. , 2016, , 125-163.		0
370	EXSCELâ€™ Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus. Diabetes, 2018, 67, 1319-P.	0.3	0
371	Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group. Diabetes, 2018, 67, 130-LB.	0.3	0
372	Prioritizing Quad Therapy and the Path Forward in Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2022, 145, 1105-1107.	1.6	0
373	International Collaborations in Heart Failure: JCF in Latin America. Journal of Cardiac Failure, 2022, 28, 695-696.	0.7	0